A Phase 1a/b Non-randomized, Dose Escalation Study of the Safety, Pharmacokinetics, and Pharmacodynamics of Sterile BPM31510 (Ubidecarenone, USP) Nanosuspension Injection Administered Intravenously to Patients With Solid Tumors
Active, no longer recruiting
Phase of Trial: Phase I
Latest Information Update: 12 Oct 2017
At a glance
- Drugs Ubidecarenone (Primary) ; Docetaxel; Fluorouracil; Folinic acid; Gemcitabine
- Indications Solid tumours
- Focus Adverse reactions
- Sponsors Berg Pharma
- 09 Oct 2017 Planned End Date changed from 1 Sep 2017 to 1 Jan 2018.
- 09 Oct 2017 Planned primary completion date changed from 1 Jun 2017 to 1 Oct 2017.
- 09 Oct 2017 Status changed from recruiting to active, no longer recruiting.